Please assess the completion status of the following clinical trial:

Trial Title: Berinert P Study of Subcutaneous Versus Intravenous Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with an established diagnosis of HAE type I (C1-Inhibitor activity \< 50% and C1-Inhibitor antigen \< 15.4 mg/dl) or HAE type II (C1-Inhibitor activity \< 50% and C1-Inhibitor antigen in normal or elevated concentration of dysfunctional protein).~* Male and female subjects with an age of at least 18 years.~* Subjects providing an informed consent.~Exclusion Criteria:~* Subjects without an established diagnosis of HAE.~* Last C1-INH administration less than 7 days ago and/or acute attack.~* Subjects with acquired angioedema (AAE).~* All other types of angioedema not associated with C1-INH deficiency.~* Treatment with any investigational drug (exclusive drugs appropriate for the treatment of acute angioedema) 30 days before study treatment.~* Treatment with any other drug appropriate for the treatment of acute angioedema within 7 days before start of study treatment at each phase.~* Danazol prophylaxis.~* Prophylaxis with antifibrinolytics, EACA, tranexamic acid.~* Subjects with a known hypersensitivity to study medication (Berinert P).~* Pregnant women (pregnancy rapid assay required for women with childbearing potential), women currently breast-feeding, or with the intention to breast-feed~* Subjects with malignant diseases.~* Subjects with immunodeficiencies such as established acquired immunodeficiency syndrome.~* Subjects with concurrent serious or acute illness or infection as per investigators judgement.~* Subjects with mental conditions which render the subject or its legally acceptable representative unable to understand the nature, scope and possible consequences of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
- 2 (Type: ACTIVE_COMPARATOR): subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.

Based on this trial design, predict the completion outcome and termination type (if applicable).